Try our beta test site

Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: September 17, 2008
Last updated: February 9, 2011
Last verified: February 2011
The purpose of this study is to evaluate the safety and efficacy of AN2728 Ointment, 5%, compared to Ointment Vehicle, applied twice daily for 12 weeks, in the treatment of plaque type psoriasis

Condition Intervention Phase
Drug: AN2728
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, 12 Week, Bilateral Study of the Safety and Efficacy of AN2728 Ointment, 5%, Versus Ointment Vehicle in the Treatment of Patients With Plaque Type Psoriasis

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Overall Target Plaque Severity Assessment (OTPSS) at Day 84 (end of treatment) [ Time Frame: Day 84 ]

Secondary Outcome Measures:
  • Overall Target Plaque Severity Assessment (OTPSS) at Days 7, 14, 28, 42, 56, 70 and 91. [ Time Frame: Days 7, 14, 28, 42, 56, 70 and 91 ]

Estimated Enrollment: 30
Study Start Date: September 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
AN2728 Ointment, 5%
Drug: AN2728
AN2728 Ointment, 5%, twice daily for 12 weeks
Other Name: AN2728 Ointment, 5%
Placebo Comparator: 2
AN2728 Ointment Vehicle
Drug: AN2728
AN2728 Ointment Vehicle, twice daily for 12 weeks
Other Name: AN2728 Ointment Vehicle

Detailed Description:
This is a single center, randomized, double-blind, vehicle-controlled, bilateral design. Patients will apply both test articles, AN2728 Ointment, 5%, and Ointment Vehicle twice daily for 12 weeks. The assigned study medication will be applied to two comparable treatment targeted plaques identified at baseline. One test article will be applied to one plaque and the other test article to an anatomically distinct plaque. All efficacy evaluations will be measured from only the two plaques identified at the baseline visit.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female >18 years of age at time of enrollment
  2. The clinical diagnosis of stable plaque psoriasis
  3. Two target plaques of similar severity

    • ≥ 5 cm2 but ≤ 100 cm2 computed by multiplying the greatest diameter of the plaque by the diameter of the plaque perpendicular to the greatest diameter
    • Bilaterally located (right/left) plaques on the arms or distinct plaques located on the trunk. Plaques located on the trunk must be separated by at least 10 cm and will be designated by the Investigator as either left/right or front/back or upper/lower
    • Overall target plaque severity score (OTPSS) of 2-4 (mild to moderate) with no more than a 1 point difference in the scores of the individual plaques
  4. Normal or not clinically significant screening laboratory results
  5. Willing and able to apply study drug as directed, comply with study instructions and commit to all follow-up visits
  6. Ability to understand, agree to and sign the study Informed Consent Form (ICF) prior to initiation of any protocol related procedures

Exclusion Criteria:

  1. Any dermatological conditions that could interfere with clinical evaluations or any disease state or physical condition which might expose the patient to an unacceptable risk by study participation
  2. Any underlying disease(s) or other dermatological conditions that require the use of exclusionary topical or systemic therapy (see below).
  3. Known sensitivity to any of the components of the study medication
  4. Spontaneously improving or rapidly deteriorating psoriatic plaques or pustular/exfoliative, guttate, erythrodermic or other non-plaque form of psoriasis
  5. Concomitant use of topical or systemic therapies that might alter the course of psoriasis
  6. Females of child bearing potential. Females must be post-menopausal or surgically sterile (oophorectomy).
  7. Washout periods of:

    • Topical drugs that might alter the course of psoriasis: 2 weeks
    • Oral retinoids: 8 weeks
    • Non-retinoid systemic drugs that might alter the course of psoriasis: 4 weeks
    • PUVA: 4 weeks
    • UVB therapy: 4 weeks
    • Use of emollients/moisturizers on area(s) to be treated: 2 days to baseline visit
  8. AIDS or AIDS related illness
  9. Concurrent participation in another drug research study or within 30 days of enrollment
  10. Use of lithium or hydroxychloroquine containing products (i.e. Plaquenil)
  11. Use of a beta-blocking medication (i.e. propranolol) if the dose has not been stabilized for at least 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00755196

Mexico City, Distrito Federal, Mexico, 06700
Sponsors and Collaborators
Study Director: Lee Zane, MD, MAS Pfizer
  More Information

Responsible Party: Lee Zane, MD, MAS, Anacor Pharmaceuticals, Inc. Identifier: NCT00755196     History of Changes
Other Study ID Numbers: AN2728-PSR-202 
Study First Received: September 17, 2008
Last Updated: February 9, 2011

Keywords provided by Pfizer:
Plaque Type Psoriasis

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases processed this record on February 27, 2017